Business Wire

Facebook Disables Ad Blockers and Now Instart Logic Makes Analogous Capability Available to Premium Digital Publishers

14.12.2016 13:00 | Business Wire

Del

Instart Logic, Inc.:

  • Ad blocker adoption grows to mainstream non-technical users – 2016 projected loss of €38.9 billion in advertising revenue globally by digital publishers (source: Adobe report, Sept 2015); ad blocking threatens business model of digital publishers of high quality free content
  • End-users install Ad Blockers to prevent annoying and intrusive ads such as pop-up videos and ads that take over the screen. However, they act as a “blunt instrument” blocking all ads including relevant and contextual ads that research shows most users don’t mind.
  • Instart Logic’s cloud-based ‘AppShield Ad Integrity’ solution circumvents ad blockers allowing premium digital publishers to monetise their sites through online advertising while delivering high quality free content; deployment requires only a simple DNS change. Solution deployed and operational in a large number of premium publishers.
  • Ad Integrity comes on heels of Facebook successfully disabling ad blockers and unlocking significant Q3 ad revenue in the process
  • Ad Integrity solution works across display and video advertisements and is transparent to ad delivery and measurement systems. No changes are required to the publisher’s existing ecosystem of ad exchanges, ad networks and ad serving systems.
  • End-user desire to remove annoying ads should be respected - many premium publishers working with Instart Logic choose to adopt limited advertising for users with ad-blockers installed.
  • Solution integrated into the world’s most advanced endpoint-aware application delivery service for high levels of performance, security and reliability with a globally-deployed delivery service

Ad blocking adoption has risen dramatically around the world putting digital publishers at risk of going out of business or having to lock all premium content behind paywalls. However, an elegant and holistic technology solution preserving the needs of both digital publishers and the digital media-consuming public has arrived to market from Instart Logic, a company that makes websites and mobile apps fast and secure. Instart Logic today announced AppShield Ad Integrity, a technology breakthrough that circumvents ad blockers so a healthy ecosystem of digital publishers of free high quality content continues to grow and thrive.

NOTE TO EDITORS: For more information, please contact Priya Patel at prpatel@instartlogic.com.

About Instart Logic

Instart Logic, Inc., is the world’s first endpoint-aware application delivery solution that makes applications fast, secure, and easy to operate. Instart Logic’s platform combines machine learning, virtualization, and open APIs with a content delivery network (CDN) for global delivery. Using Instart Logic, enterprises can provide ultra-fast, visually immersive and secure experiences on any device to maximize revenue, deliver superior customer experiences and gain competitive advantage. Instart Logic is funded by Andreessen Horowitz, Four Rivers Group, Geodesic Capital, Greylock Partners, Hermes Growth Partners, Kleiner Perkins Caufield & Byers, Sutter Hill Ventures, Telstra Ventures, Tenaya Capital, Wing Venture Capital and several notable Silicon Valley angel investors. Learn more at https://www.instartlogic.com or follow us on Twitter at @InstartLogic.

Contact information

Instart Logic, Inc.
Priya Patel, +44 (0) 7984 789 674
prpatel@instartlogic.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

European Commission Grants New Indication for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)21.8.2017 13:25Pressemelding

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) approved the extension of the indication for Soliris® (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Soliris is the first and only complement-based therapy approved in the European Union (EU) for this ultra-rare subset of patients.1-4 Patients with refractory gMG can have difficulties walking, talking, swallowing and breathing normally despite therapies currently used for MG. Exacerbations and crises of their disease may require hospitalization and intensive care and may be life-threatening.5-7 Soliris will be launched for this new indication initially in Germany, and Alexion is evaluating launches in additional EU countries. “Patients with refractory gMG have exhausted multiple the

IntegenX Applauds the Passage of the Rapid DNA Act of 201721.8.2017 12:00Pressemelding

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations. Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement. IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman

PPG Completes COLORFUL COMMUNITIES Project at Primary School in Kecskemét, Hungary21.8.2017 08:03Pressemelding

PPG (NYSE:PPG) today announced the completion of a COLORFUL COMMUNITIES™ project in Kecskemét, Hungary, that helped revitalize the learning environment of the Corvin Mátyás primary school. The Colorful Communities program provides PPG volunteers and products along with financial contributions to bring color and vitality to communities where the company operates around the world, such as in Kecskemét, where the PPG automotive service team operates with 33 employees. The project brought together more than 140 PPG and community volunteers who spent three days at the school revitalizing four classrooms, four changing rooms and the playground. PPG provided more than $20,000 to assist with the project, including more than 460 liters of Héra ® Prémium waterborne interior paint and Trinát ® Aqua wate

Glennmont Partners Completes Refinancing of Sleaford Biomass Plant for £150m21.8.2017 08:00Pressemelding

Glennmont Partners has successfully completed the refinancing of the Sleaford Renewable Energy Plant on behalf of its dedicated clean energy fund, Glennmont Clean Energy Fund Europe I, as part of a programme of realisations of value from the Fund. Glennmont Partners is one of Europe’s largest fund managers focusing exclusively on investment in clean energy infrastructure. Glennmont raises long-term capital to invest in alternative power generation projects including wind farms, biomass power stations, solar parks and small-scale hydro power plants. The carefully selected, risk managed investments deliver sustained performance and predictable returns over periods of 10 years or more. Sleaford REP is a 40MWe straw-fired biomass plant located in Lincolnshire, UK. The plant has been in operation since 2014 and is being operated by Burmeister & Wain Scandinavian Contractor (BWSC). The

Boehringer Ingelheim: Advancing anticoagulation care with new data at ESC Congress 201721.8.2017 07:08Pressemelding

Boehringer Ingelheim today announced that it will present important new data on the treatment of patients with atrial fibrillation (AF) at the ESC Congress in Barcelona, Spain, 26-30 August 2017. In total, four abstracts have been accepted, investigating different aspects of AF patient treatment. The results of the RE-DUAL PCI™ trial have been selected for one of the Late Breaking Science sessions of the congress. The RE-DUAL PCI™ trial compared dual therapy with triple therapy after percutaneous coronary intervention (PCI) with stent placement in approximately 2,500 adults with atrial fibrillation. Patients were either treated with dabigatran etexilate (Pradaxa®) and a single antiplatelet agent or with the vitamin K antagonist (VKA) warfarin and two antiplatelets. The dabigatran doses investigated in this trial are the same doses which have already demonstrated effective stroke preven

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom